Highlights Inhibrx, Inc.

Equities

INBX

US45720L1070

Real-time Estimate Cboe BZX Other stock markets 12:00:35 2024-04-30 pm EDT			5-day change	1st Jan Change
34.31 ^USD	+0.44%		+0.35%	-9.87%

Feb. 28	Inhibrx Shares Fall After Q4 Net Loss Widens	MT
Feb. 28	Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inhibrx Shares Fall After Q4 Net Loss Widens	Feb. 28	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	Feb. 28	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	Feb. 01	AN
Health Care Flat After J&J Earnings -- Health Care Roundup	Jan. 23	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	Jan. 23	AN
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	Jan. 23	MT
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET	Jan. 23	DJ
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak	Jan. 23	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	Jan. 23	DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion	Jan. 23	MT
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	Jan. 23	DJ
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET	Jan. 23	DJ
Sanofi: agreement to acquire Inhibrx	Jan. 23	CF
Sanofi to Buy US-based Biopharmaceutical Group Inhibrx for $1.7 Billion	Jan. 23	MT
France's Sanofi to buy U.S. drugs project INBRX-101 for around $2.2 bln	Jan. 23	RE
Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. for $1.4 billion.	Jan. 22	CI
Inhibrx, Inc. entered into a Separation and Distribution Agreement to spin off 92% stake in All non-101 assets and liabilities.	Jan. 21	CI
Inhibrx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inhibrx, Inc.

Equities

INBX

US45720L1070

Highlights

Filters